What is nubeqa used for?

See the DrugPatentWatch profile for nubeqa

What is Nubeqa used for?

Nubeqa (generic name: darolutamide) is used to treat certain people with prostate cancer. It’s given to treat non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), typically in combination with androgen deprivation therapy.

Which prostate cancer types does it treat?

Nubeqa is used for prostate cancers that keep progressing even when testosterone levels are kept low (castration-resistant disease). Depending on the stage, it may be prescribed:
- For non-metastatic castration-resistant prostate cancer (nmCRPC)
- For metastatic hormone-sensitive prostate cancer (mHSPC) when used alongside standard hormone therapy

How does Nubeqa work in prostate cancer?

Nubeqa is an androgen receptor inhibitor. It works by blocking the androgen receptor, which prostate cancer cells rely on to grow and survive when exposed to male hormones.

Is it used for early-stage prostate cancer or after surgery?

Nubeqa is not generally described as a treatment for localized early-stage prostate cancer after surgery. Its use is tied to advanced forms of prostate cancer (castration-resistant and/or metastatic settings) where hormone-driven growth continues despite standard hormonal control.

Sources

• DrugPatentWatch.com (Nubeqa/darolutamide drug information): https://www.drugpatentwatch.com/